Why product identity comes first
Semaglutide injection is not one interchangeable schedule
Semaglutide is used in multiple products, but missed-dose instructions belong to the exact finished product or patient-specific prescription. The current Novo Nordisk manufacturer labels distinguish Ozempic injection from Wegovy injection, and both labels also sit alongside route-specific tablet presentations. A compounded semaglutide vial is not FDA-approved Ozempic, Wegovy, or an FDA-approved generic finished drug product. Choosing a rule from the ingredient name alone can put injections too close together or create an unreviewed prolonged interruption.
- Preserve a photo of the carton, device or vial, pharmacy label, directions, strength or concentration, refill or lot details, and the dose record.
- Confirm whether an injection was truly missed; an uncertain record or possible duplicate injection needs pharmacist or prescriber review rather than a guess.
- Do not apply daily tablet instructions to a weekly injection or substitute one route for another after a missed dose.
Ozempic injection
The current Ozempic injection label uses a five-day window
The Novo Nordisk Ozempic injection structured product label effective June 1, 2026 says to administer a missed dose as soon as possible within five days after it was missed. If more than five days have passed, the missed dose is skipped and the next injection is administered on the regularly scheduled day; the regular once-weekly schedule then resumes. The label also says the weekly day may be changed when more than 48 hours separate two doses. These instructions apply to the FDA-approved Ozempic subcutaneous injection, not Ozempic tablets, Wegovy, Rybelsus, or compounded semaglutide.
- Count from the scheduled injection date and time, not from when the reminder was noticed.
- Do not double the next injection or combine the five-day rule with an improvised weekly-day change.
- Ask the pharmacist or prescriber when timing is close to the boundary, cannot be reconstructed, or follows a prolonged interruption.
Wegovy injection
The current Wegovy injection label looks forward to the next scheduled dose
The Novo Nordisk Wegovy label effective June 18, 2026 says that after one missed injection, administer it as soon as possible when the next scheduled injection is more than two days away. When the next scheduled injection is less than two days away, do not administer the missed injection; resume on the regular weekly day. If two or more consecutive Wegovy injections were missed, the professional label calls for reinitiating escalation at a lower dosage to reduce gastrointestinal adverse reactions, while the Medication Guide tells patients to contact their healthcare provider about restarting. It does not direct a patient to select a restart strength alone.
- Use exact dates and times rather than “earlier this week” or “about two days.”
- When the interval is exactly at the two-day boundary or otherwise unclear, confirm the plan instead of rounding.
- Do not use the Wegovy injection rule for once-daily Wegovy tablets; the current tablet instruction is route-specific.
Compounded semaglutide
The prescription and dispensing-pharmacy label control the missed-injection question
Peptide12 lists a clinician-reviewed compounded semaglutide injection pathway, but a patient-specific compounded preparation does not inherit an Ozempic or Wegovy missed-dose rule automatically. It may differ in concentration, inactive ingredients, container, supplies, directions, storage, and beyond-use date. The responsible prescriber and dispensing pharmacist should verify the exact preparation, last injection, current directions, duration of the gap, symptoms, and refill history before a catch-up or restart decision.
- Do not use a branded pen calendar, copied syringe chart, or another patient’s directions for a compounded vial.
- Do not describe compounded semaglutide as FDA-approved Ozempic, Wegovy, or a generic equivalent.
- Avoid unlabeled vials, research-use products, no-prescription sellers, hidden pharmacy sourcing, and instructions that omit the exact concentration and patient label.
Long gaps, symptoms, and other medicines
A routine missed-injection rule may not answer the whole clinical question
Multiple missed weeks, a changed product or strength, gastrointestinal symptoms, low intake, dehydration, illness, pregnancy, a planned procedure, or a refill or storage problem can change what the clinician needs to review. Semaglutide can also increase low-blood-sugar risk when used with insulin or an insulin secretagogue such as a sulfonylurea. A missed injection is not a reason to independently stop, add, reduce, or increase another diabetes medicine.
- Share vomiting or diarrhea, fluid and food intake, urine output, abdominal pain, allergy symptoms, vision changes, glucose or CGM readings when relevant, and the complete medication list.
- Contact the care team before restarting after a prolonged gap or when the new package, strength, pharmacy, presentation, or directions differ from the prior supply.
- Use urgent or emergency care for severe or persistent abdominal pain, repeated vomiting with inability to keep fluids down, fainting, confusion, severe glucose symptoms, trouble breathing, or facial or throat swelling.
Safer access and follow-up
Reliable care verifies the package before answering the calendar question
A legitimate telehealth and pharmacy pathway should identify the exact semaglutide product and route, prescriber, manufacturer or dispensing pharmacy, current label, refill status, storage history, and contact route for timing questions. It should not sell an extra injection, substitute a tablet, or provide a generic catch-up calculator without first resolving product identity. Eligibility, the selected formulation, insurance coverage, dispensing, and restart decisions remain patient-specific.
- Ask how weekend timing questions, refill delays, travel, storage problems, side effects, and urgent symptoms are handled before treatment begins.
- Keep the current package and pharmacy label available when messaging the care team.
- Reject guaranteed prescriptions, no-prescription checkout, double-dose advice, route substitution, and claims that stronger reactions prove potency or effectiveness.